Last reviewed: June 1, 2026

Last updated: June 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide injections are not appropriate for everyone. Patients with a personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia type 2 (MEN2), or certain metabolic conditions should avoid this medication. Understanding who should not take semaglutide is critical for safe, effective weight management.

Beyond standard medical screening, emerging evidence suggests genetic factors in GLP-1 and related peptide pathways may influence how individuals respond to or tolerate semaglutide. PlexusDx takes a precision-wellness approach: combining clinical contraindication assessment with genetic predisposition insights to support more personalized conversations between patients and their healthcare providers.

Absolute Contraindications: Who Must Avoid Semaglutide

Absolute contraindications are conditions where semaglutide use carries unacceptable risk. Patients with personal history of medullary thyroid carcinoma or a family history of MTC must not use semaglutide. Additionally, individuals diagnosed with multiple endocrine neoplasia type 2 (MEN2A or MEN2B) should avoid this medication entirely.

The FDA black box warning reflects data from animal studies suggesting GLP-1 receptor agonists may increase thyroid C-cell proliferation. While human evidence of MTC causation remains limited, the precautionary principle supports absolute avoidance in high-risk populations. These contraindications are non-negotiable and require careful medical history review before initiating treatment.

Relative Contraindications and Risk Factors: Clinical Decision-Making Framework

Relative contraindications include conditions where semaglutide may be used with caution and close monitoring, but require individualized risk-benefit assessment. These include personal or family history of thyroid nodules, chronic pancreatitis, severe renal impairment, and uncontrolled diabetic retinopathy. Pregnancy and breastfeeding are also important relative considerations requiring careful planning and provider guidance.

Additionally, patients with a history of medullary thyroid cancer in first-degree relatives, those with severe gastrointestinal disease, or individuals experiencing significant dehydration risk should undergo thorough evaluation before proceeding. The decision to use semaglutide in these cases should be made collaboratively with a qualified healthcare provider who can weigh individual circumstances and monitor closely.

Risk Factor or Condition Clinical Consideration
Personal or family history of medullary thyroid carcinoma Absolute contraindication—do not use semaglutide
Multiple endocrine neoplasia type 2 (MEN2) Absolute contraindication—do not use semaglutide
History of thyroid nodules or abnormal TSH Relative contraindication—requires baseline imaging and monitoring
Chronic or acute pancreatitis Relative contraindication—heightened risk of pancreatitis exacerbation
Severe renal impairment (eGFR <15) Relative contraindication—limited safety data; dose adjustment may be needed
Diabetic retinopathy (severe or uncontrolled) Relative contraindication—rapid glucose lowering may worsen vision temporarily
Pregnancy or breastfeeding Relative contraindication—insufficient safety data in these populations
Severe gastrointestinal disorders Relative contraindication—GI side effects may be poorly tolerated

Metabolic and Genetic Predispositions: How Individual Differences Matter

Individual genetic variations in peptide pathways—such as GLP1R, GIPR, FTO, and MC4R genes—may influence how a patient metabolizes or responds to semaglutide. While genetic predisposition does not predict exact medication response, these variants can help provide context for why certain individuals experience side effects more readily or show variable efficacy patterns.

Patients with genetic predispositions toward higher appetite drive (FTO variants) or altered GLP-1 receptor sensitivity may have different starting points for semaglutide dosing or tolerance profiles. Understanding these predispositions can support a more informed conversation with your provider about whether compounded semaglutide is the right choice, or whether an alternative GLP-1 agent might be better suited to your genetic and metabolic profile.

Special Populations and Safety Considerations

Older adults, patients with significant weight loss history, and those with a personal history of eating disorders require additional screening before semaglutide use. Rapid weight loss from GLP-1 therapy can unmask latent eating disorder behaviors or psychological vulnerabilities. Patients on concurrent insulin or certain diabetes medications also face increased hypoglycemia risk and require dose adjustments and closer monitoring.

Dehydration is a common semaglutide side effect that can elevate acute kidney injury risk, especially in older adults or those with pre-existing renal compromise. Patients with active gallbladder disease, severe liver impairment, or uncontrolled high blood pressure should discuss semaglutide candidacy carefully with their provider. A thorough medical and psychiatric history is essential before initiating any GLP-1 therapy.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) genes to help reveal predispositions in peptide-related metabolic pathways. While genetic variants do not determine whether you should or should not use semaglutide, they may help provide context for how your body might respond to GLP-1 therapy and support a more personalized conversation with your provider.

The genetic test predicts predispositions in these peptide pathways—not exact medication response or safety outcomes. For example, certain FTO variants are associated with higher baseline appetite drive, while specific GLP1R variants may relate to differential receptor sensitivity. This information should be interpreted with a qualified healthcare provider and combined with complete medical screening to inform treatment decisions.

If you have relative contraindications or a complex medical history, PlexusDx genetic insights can complement your provider's clinical assessment. Understanding your peptide pathway predispositions may help clarify whether compounded semaglutide aligns with your genetic and metabolic profile, or whether alternative peptide formulations (such as tirzepatide or microdose GLP-1 protocols) might support a more tailored approach.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $229-$309/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves